Cordlife has announced the renewal of its cord blood banking service (CBBS) licence for one year and its human tissue banking service licence for two years, effective from 14 January 2026. The Ministry of Health’s decision includes conditions imposed last November, focusing on the storage, retrieval, and disposal of cord blood units, as well as facilitating client-requested transfers.
Cordlife’s Group Executive Director and CEO, Shally Chen Xiaoling, expressed gratitude for the renewal, stating, “The team has worked very hard in the last year to strengthen our operations, bring in experienced staff and retrain our existing team.” She emphasised the company’s commitment to complying with all conditions and restoring stakeholder confidence.
The conditions apply solely to Cordlife’s Singapore operations, leaving its regional businesses unaffected. Cordlife continues to enhance its governance, operational controls, and compliance processes, ensuring high standards of safety and care. The company is also actively searching for a new Clinical Governance Officer.
In response to a previous temperature excursion incident, Cordlife has offered affected customers refunds and an enhanced package, which includes five additional years of free storage and compensation of up to $100,000 for medical conditions requiring stem cell transplants.
Cordlife, founded in 2001, operates Asia’s largest network of private cord blood banks and is a market leader in several countries, including Hong Kong, Indonesia, and the Philippines. The company remains focused on innovation, quality, and customer satisfaction in its services.
